Please assess the completion status of the following clinical trial:

Trial Title: Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previously diagnosed (e.g. more than 6 months ago) primary adrenal insufficiency with a stable daily glucocorticoid substitution dose for at least 3 months prior to study entry~* Signed informed consent to participate in the study.~Exclusion Criteria:~* Clinical or laboratory signs of significant cerebral, cardiovascular, respiratory, Hepatobiliary, pancreatic disease~* Clinically significant renal dysfunction~* Clinical or laboratory signs of significant gastrointestinal emptying or motility disease~* Any medication with agents which could interfere with hydrocortisone kinetics~* Pregnant or lactating women~* Regular dehydroepiandrosterone (DHEA) medication for the past 4 weeks~* Oral oestrogen medication for the past 4 weeks~* Deranged mineralocorticoid status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Novel once daily modified release (Type: EXPERIMENTAL): Test drug: hydrocortisone (modified release), oral tablet, available as 20 mg and 5 mg.~The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state
- Conventional TID hydrocortisone (Type: ACTIVE_COMPARATOR): Reference drug: hydrocortisone, oral tablet, 10 mg. The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM)in the same total daily dose as the experimental drug. The morning dose was administered in the fasting state.

Based on this trial design, predict the completion outcome and termination type (if applicable).